Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clonazepam for ARID1B-related intellectual disability
2019-003558-98Phase 2Completed
- Sponsor
- Centre for Human Drug Research
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clonazepam in ARID1B-related intellectual disability (ARID1B-ID) (2 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Serum clonazepam pharmacokinetics, Saliva clonazepam pharmacokinetics and 1 more. Started Jan 2020; status: completed.
02
Drugs
clonazepam
03
Conditions
ARID1B-related intellectual disability (ARID1B-ID)
Beyond the preview
Go deeper on 2019-003558-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003558-98.